somatotroph is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2026-05-30. Where a claim depends on a specific study, the study is described rather than over-claimed.
The drug affinity complex is a maleimidopropionic acid group attached to a lysine side chain. It reacts with the free thiol of cysteine-34 on circulating albumin, forming a covalent bond. This conjugation keeps the peptide in the bloodstream and shields it from rapid renal filtration and proteolysis. Reported circulation half-lives for the albumin-bound form fall in the range of roughly six to nine days in early human studies.
Binding to GHRH receptors on pituitary somatotroph cells triggers cyclic AMP signaling and stimulates growth hormone synthesis and release. Because the peptide acts upstream of the pituitary, effects are mediated through endogenous growth hormone rather than direct receptor activation in peripheral tissues. Increases in insulin-like growth factor 1 are generally described as a downstream consequence. Most published human exposure data come from small early-stage studies, and the clinical significance of the pharmacokinetic profile remains incompletely characterized.
The peptide backbone includes a D-alanine at position two, which resists cleavage by dipeptidyl peptidase IV, and several other substitutions that reduce degradation. Its molecular weight is roughly 3.4 kDa without the linker and about 3.6 kDa with it. The molecule is water soluble and is normally supplied as a lyophilized powder. Precise sequence and mass values depend on which variant is described, so technical documents usually state the exact form being referenced.
CJC-1295 is a synthetic peptide designed as a long-acting analogue of growth hormone-releasing hormone (GHRH). Its structure derives from the first 29 amino acids of native GHRH, a fragment often called GRF(1-29). Four substitutions were introduced to slow enzymatic breakdown and extend activity relative to the natural sequence. The compound was developed by ConjuChem as part of a broader effort to improve the pharmacokinetic profile of peptide hormones. It is studied in laboratory and clinical research settings rather than appearing as a naturally occurring substance.
| Property | Value | Notes |
|---|---|---|
| Physical form | Lyophilized white powder | Supplied as a freeze-dried solid for research use |
| Molecular weight | Approximately 3,647 Da (DAC form) | Lower for the variant lacking the albumin-binding moiety |
| Solubility | Soluble in water and aqueous buffer | Typically dissolved in sterile or bacteriostatic water |
| Typical storage temperature | −20 °C or below | Dry powder, desiccated and protected from light |
| Common analytical method | Reversed-phase HPLC with mass spectrometry | Used for purity estimation and identity confirmation |
The albumin-binding version stays in circulation for days, because covalent attachment to serum albumin shields the peptide from rapid filtration and degradation. Reported half-lives for this form fall in the range of several days. The version without the linker is cleared in minutes, with estimates often near thirty minutes in animal work. These figures come from small studies and vary with assay method, species, and route, so they are best read as approximate rather than fixed constants.
Studies in this area generally track growth hormone pulses, insulin-like growth factor 1 concentrations, and occasionally body composition endpoints. Most published human data come from early, small trials, and questions about long-term effects remain open. Whether repeated exposure alters pituitary responsiveness over time is not settled. Analytical work relies on immunoassays for the hormones and on mass spectrometry for the peptide itself, because the two measurements answer different questions.
Receptor level activity follows the canonical GHRH pathway. The peptide binds the GHRH receptor, a class B G protein coupled receptor on somatotroph cells of the anterior pituitary. Binding raises intracellular cyclic AMP, which promotes calcium entry and the release of growth hormone into the bloodstream. Because the molecule acts at the same receptor as the endogenous hormone, its effect is superimposed on the natural pulsatile rhythm rather than replacing it. Whether sustained receptor occupation leads to desensitization is not fully settled.
CJC-1295 belongs to a class of synthetic peptides modeled on growth hormone releasing hormone, a forty-four amino acid signal produced by the hypothalamus. The compound is built from the first twenty-nine residues of the natural sequence, with four substitutions introduced at positions 2, 8, 15 and 27. These changes were designed to slow enzymatic breakdown while preserving receptor activation. The result is a peptide that is shorter than native GHRH and considerably more resistant to ordinary clearance pathways in circulation.
Downstream of growth hormone, the liver and other tissues increase production of insulin-like growth factor 1, a mediator of many growth-promoting effects. Studies have documented elevated levels of both hormones after dosing, and the rise from the long-acting form persists longer than that produced by shorter-acting analogues. What remains unclear is whether sustained elevation of these markers translates into meaningful clinical benefit, and whether prolonged exposure carries risks that short trials could not detect.
CJC-1295 acts at the growth hormone-releasing hormone receptor, a G-protein-coupled receptor found on somatotroph cells in the anterior pituitary. Binding triggers a rise in cyclic AMP and calcium entry, which promotes release of stored growth hormone. Because the peptide mimics the body's own releasing hormone, it amplifies existing secretory pulses rather than driving continuous output. The size of the response therefore depends partly on the subject's own hormonal rhythm and feedback state.
== Binding assays == Measuring the extent and kinetics of radioligand binding is important in determining information about binding sites of radioligands, and subsequent affinity to potential drugs. Three different binding assays are typically used for radioligand binding: saturation, competition, and kinetic binding.
== History == The company was incorporated in January 2006 as Phluid, Inc. and changed its name to Tandem Diabetes Care in 2008. Former Biosite executive Kim Blickenstaff joined as president and chief executive officer in 2007. Its first product was designed following interviews with pump users and clinicians and used a color touchscreen rather than the button-based interfaces then common on insulin pumps. The Food and Drug Administration (FDA) cleared the t:slim insulin-delivery system in November 2011, and Tandem began selling it in the United States the following year. In November 2013, Tandem sold eight million shares at $15 each in its initial public offering, raising approximately $108 million after costs. Tandem began shipping the software-updatable t:slim X2 in 2016. The FDA subsequently authorized versions that displayed readings from the Dexcom G5 and G6 CGMs, and in 2019 classified the t:slim X2 as the first alternate controller enabled insulin pump, a category designed to support interoperable diabetes devices. John Sheridan, previously the company's chief operating officer, succeeded Blickenstaff as president and CEO in March 2019. The company acquired the diabetes-data application Sugarmate in June 2020. It acquired infusion-set developer Capillary Biomedical for $24.7 million in July 2022 and Swiss patch-pump developer AMF Medical in January 2023. AMF had been developing Sigi, a rechargeable patch pump that used prefilled insulin cartridges; the product remained in development at the end of 2025.
=== Organosilanes === Organosilanes create a network of electrically charged molecules on the surface, which rupture the cell wall on contact. This is due to their structure which consists of a hydrophobic element and a cationic element. While the hydrophobic element may prevent adherence in the first place, it may also intercalate with the cell wall, whose rupture is aided by the cationic component.
The war has severely weakened Yemen’s health system. More than half of the country’s health facilities have been reported as non-functional, a situation attributed to airstrikes, damage to buildings, departures or non-payment of staff, and long-term shortages of medicines and equipment.Facilities that continue to operate frequently do so under difficult conditions, facing unreliable electricity, scarce fuel for generators and obstacles in maintaining hygiene standards or cold-chain storage. Researchers link these operation difficulties to port restrictions, disrupted supply chains and the broader economic crisis. This institutional collapse has coincided with a series of major epidemics. Yemen has experienced what many researchers describe as the largest recorded cholera outbreak in modern times, with over one million suspected cases and earlier World Health Organization estimates of more than 600,000 cases with over 2,000 deaths. The spread of cholera has been associated with the destruction of water treatment plants, malfunctioning sewage systems and fuel shortages that hindered water pumping and waste disposal. Interruptions in vaccination campaigns and the wider deterioration of primary health care also facilitated outbreaks of diphtheria and measles,while when the COVID-19 pandemic reached Yemen, observers reported delayed vaccine delivery, limited testing capacity and additional economic pressure due to rising prices and economic stagnation.
== Measurement == Follicle-stimulating hormone is typically measured in the early follicular phase of the menstrual cycle, typically day three to five, counted from last menstruation. At this time, the levels of estradiol (E2) and progesterone are at the lowest point of the menstrual cycle. FSH levels in this time is often called basal FSH levels, to distinguish from the increased levels when approaching ovulation. FSH is measured in international units (IU). For Human Urinary FSH, one IU is defined as the amount of FSH that has an activity corresponding to 0.11388 mg of pure Human Urinary FSH. For recombinant FSH, one IU corresponds to approximately 0.065 to 0.075 μg of a "fill-by-mass" product. The mean values for women before ovulation are around (3.8-8.8) IU/L. After ovulation these levels drop to between (1.8-5.1) IU/L. At the mid of the menstrual cycle it reaches its highest value, between (4.5-22.5) IU/L. During menopause, the values goes up even more, between (16.74-113.59) IU/L. For men, the mean values are around (1.5-12.4) IU/L.
Sources: en.wikipedia.org
== Mechanism == Seborrhoeic dermatitis is a complex condition with many interacting factors that are not yet fully explained. In general, the major factors that influence the development and severity include Malassezia yeast present on and in the skin, skin production of oily sebum, and a subsequent inflammatory response against Malassezia and their byproducts. Additional factors involved in the condition are a compromised skin barrier, the makeup and amount of sebum produced, the character of the immune response and inflammation, and the presence of other microbe species inhabiting the skin. A suggested series of events leading to seborrhoeic dermatitis is an initially damaged skin barrier and abnormal sebum production, which leads to a change in the microbiome of the skin that in turn elicits an immune response. An alternative explanation is an increase in sebum production feeding an increase in the Malassezia population that instigates inflammation; the inflammation then causes cellular changes that damage the skin barrier. This barrier disruption then encourages additional Malassezia growth and inflammation and again worsens skin barrier function.
=== 1949 === January 5–8: The Council for Economic Mutual Assistance (Comecon) formed. March 8: The Élysée Accords recognize Vietnam as an associated state within the French Union. April 4: The North Atlantic Treaty Organization (NATO) is founded by Belgium, Canada, Denmark, France, Iceland, Italy, Luxembourg, the Netherlands, Norway, Portugal, the United Kingdom, and the United States, in order to resist Communist expansion. May 11: The Soviet blockade of Berlin ends with the re-opening of access routes to Berlin. The airlift continues until September, in case the Soviets re-establish the blockade. Brune argues, "Moscow realized the blockade had not been successful – it had drawn the Western powers closer together rather than dividing them. Finally, Western countermeasures had inflicted considerable damage on the economic life of East Germany and the other Soviet satellites." May 23: In Germany, the Bizone merges with the French zone of control to form the Federal Republic of Germany, with Bonn as its capital. June 14: The State of Vietnam is proclaimed. July 20: The 1948 Arab–Israeli War ends with an Israeli victory. As a result of the war, the Transjordanians annex the West Bank and Egypt occupies the Gaza Strip, turning it into the All-Palestine Protectorate. August 29: The Soviet Union tests its first atomic bomb. The test, known to Americans as Joe 1, succeeds, as the Soviet Union becomes the world's second nuclear power. September 13: The USSR vetoes the United Nations membership of Ceylon, Finland, Iceland, Italy, Jordan, and Portugal.
By the 17th century, water pump designs had improved to the point that they produced measurable vacuums, but this was not immediately understood. What was known was that suction pumps could not pull water beyond a certain height: 18 Florentine yards according to a measurement taken around 1635, or about 34 feet (10 m). This limit was a concern in irrigation projects, mine drainage, and decorative water fountains planned by the Duke of Tuscany, so the duke commissioned Galileo Galilei to investigate the problem. Galileo suggested, incorrectly, in his Two New Sciences (1638) that the column of a water pump will break of its own weight when the water has been lifted to 34 feet. Other scientists took up the challenge, including Gasparo Berti, who replicated it by building the first water barometer in Rome in 1639. Berti's barometer produced a vacuum above the water column, but he could not explain it. A breakthrough was made by Galileo's student Evangelista Torricelli in 1643. Building upon Galileo's notes, he built the first mercury barometer and wrote a convincing argument that the space at the top was a vacuum. The height of the column was then limited to the maximum weight that atmospheric pressure could support; this is the limiting height of a suction pump. In 1650, Otto von Guericke invented the first vacuum pump. Four years later, he conducted his famous Magdeburg hemispheres experiment, showing that teams of horses could not separate two hemispheres from which the air had been evacuated.
===== MeSH D08.811.277.352 – esterases (EC 3.1) ===== MeSH D08.811.277.352.100 – carboxylic-ester hydrolases MeSH D08.811.277.352.100.050 – acetylesterase MeSH D08.811.277.352.100.100 – carboxylesterase MeSH D08.811.277.352.100.150 – cholesterol esterase MeSH D08.811.277.352.100.170 – cholinesterases MeSH D08.811.277.352.100.170.176 – acetylcholinesterase MeSH D08.811.277.352.100.170.250 – butyrylcholinesterase MeSH D08.811.277.352.100.170.710 – pseudocholinesterase MeSH D08.811.277.352.100.220 – dehydroascorbatase MeSH D08.811.277.352.100.400 – lipase MeSH D08.811.277.352.100.400.745 – pancrelipase MeSH D08.811.277.352.100.430 – lipoprotein lipase MeSH D08.811.277.352.100.500 – monoacylglycerol lipases MeSH D08.811.277.352.100.550 – naphthol as d esterase MeSH D08.811.277.352.100.680 – phospholipases MeSH D08.811.277.352.100.680.510 – lysophospholipase MeSH D08.811.277.352.100.680.750 – phospholipases a MeSH D08.811.277.352.100.680.750.500 – 1-alkyl-2-acetylglycerophosphocholine esterase MeSH D08.811.277.352.335 – deoxyribonucleases MeSH D08.811.277.352.335.350 – endodeoxyribonucleases MeSH D08.811.277.352.335.350.025 – aspergillus nuclease s1 MeSH D08.811.277.352.335.350.137 – deoxyribonuclease (pyrimidine dimer) MeSH D08.811.277.352.335.350.250 – deoxyribonuclease i MeSH D08.811.277.352.335.350.250.900 – streptodornase and streptokinase MeSH D08.811.277.352.335.350.275 – deoxyribonuclease iv (phage t4-induced) MeSH D08.811.277.352.335.350.300 – dna restriction enzymes MeSH D08.811.277.352.335.350.300.250 – deoxyribonucleases, type i site-specific MeSH D08.811.277.352.335.350.300.260 – deoxyribonucleases, type ii site-specific MeSH D08.811.277.352.335.350.300.260.240 – deoxyribonuclease bamhi MeSH D08.811.277.352.335.350.300.260.250 – deoxyribonuclease ecori MeSH D08.811.277.352.335.350.300.260.260 – deoxyribonuclease hindiii MeSH D08.811.277.352.335.350.300.260.300 – deoxyribonuclease hpaii MeSH D08.811.277.352.335.350.300.270 – deoxyribonucleases, type iii site-specific MeSH D08.811.277.352.335.350.400 – holliday junction resolvases MeSH D08.811.277.352.335.350.500 – micrococcal nuclease MeSH D08.811.277.352.335.375 – exodeoxyribonucleases MeSH D08.811.277.352.335.375.750 – exodeoxyribonuclease V MeSH D08.811.277.352.355 – endonucleases MeSH D08.811.277.352.355.325 – endodeoxyribonucleases MeSH D08.811.277.352.355.325.025 – aspergillus nuclease s1 MeSH D08.811.277.352.355.325.300 – dna restriction enzymes MeSH D08.811.277.352.355.325.300.250 – deoxyribonucleases, type i site-specific MeSH D08.811.277.352.355.325.300.260 – deoxyribonucleases, type ii site-specific MeSH D08.811.277.352.355.325.300.260.240 – deoxyribonuclease bamhi MeSH D08.811.277.352.355.325.300.260.250 – deoxyribonuclease ecori MeSH D08.811.277.352.355.325.300.260.260 – deoxyribonuclease hindiii MeSH D08.811.277.352.355.325.300.260.300 – deoxyribonuclease hpaii MeSH D08.811.277.352.355.325.300.270 – deoxyribonucleases, type iii site-specific MeSH D08.811.277.352.355.325.350 – flap endonucleases MeSH D08.811.277.352.355.325.400 – holliday junction resolvases MeSH D08.811.277.352.355.325.500 – micrococcal nuclease MeSH D08.811.277.352.355.350 – endoribonucleases MeSH D08.811.277.352.355.350.025 – aspergillus nuclease s1 MeSH D08.811.277.352.355.350.500 – micrococcal nuclease MeSH D08.811.277.352.355.350.700 – ribonuclease h, calf thymus MeSH D08.811.277.352.355.350.715 – ribonuclease, pancreatic MeSH D08.811.277.352.355.350.725 – ribonuclease t1 MeSH D08.811.277.352.355.350.810 – RNA-induced silencing complex MeSH D08.811.277.352.365 – exonucleases MeSH D08.811.277.352.365.290 – exodeoxyribonucleases MeSH D08.811.277.352.365.300 – exoribonucleases MeSH D08.811.277.352.640 – phosphoric diester hydrolases MeSH D08.811.277.352.640.050 – annexin A3 MeSH D08.811.277.352.640.125 – 3',5'-cyclic-GMP phosphodiesterase MeSH D08.811.277.352.640.150 – 3',5'-cyclic-nucleotide phosphodiesterase MeSH D08.811.277.352.640.160 – 2',3'-cyclic-nucleotide phosphodiesterases MeSH D08.811.277.352.640.295 – glycerophosphoinositol inositolphosphodiesterase MeSH D08.811.277.352.640.430 – phosphodiesterase i MeSH D08.811.277.352.640.700 – phospholipases MeSH D08.811.277.352.640.700.700 – phospholipase c MeSH D08.811.277.352.640.700.700.500 – phosphatidylinositol diacylglycerol-lyase MeSH D08.811.277.352.640.700.700.750 – phospholipase c gamma MeSH D08.811.277.352.640.700.710 – phospholipase d MeSH D08.811.277.352.640.750 – sphingomyelin phosphodiesterase MeSH D08.811.277.352.650 – phosphoric monoester hydrolases MeSH D08.811.277.352.650.025 – acid phosphatase MeSH D08.811.277.352.650.035 – alkaline phosphatase MeSH D08.811.277.352.650.200 – fructose-bisphosphatase MeSH D08.811.277.352.650.225 – glucose-6-phosphatase MeSH D08.811.277.352.650.300 – histidinol-phosphatase MeSH D08.811.277.352.650.575 – 4-nitrophenylphosphatase MeSH D08.811.277.352.650.600 – nucleotidases MeSH D08.811.277.352.650.600.600 – 5'-nucleotidase MeSH D08.811.277.352.650.620 – phosphatidate phosphatase MeSH D08.811.277.352.650.622 – phosphofructokinase-2 MeSH D08.811.277.352.650.625 – phosphoprotein phosphatase MeSH D08.811.277.352.650.625.150 – calcineurin MeSH D08.811.277.352.650.625.300 – glycogen-synthase-d phosphatase MeSH D08.811.277.352.650.625.475 – myosin light-chain phosphatase MeSH D08.811.277.352.650.625.650 – phosphorylase phosphatase MeSH D08.811.277.352.650.625.700 – protein-tyrosine-phosphatase MeSH D08.811.277.352.650.625.700.150 – antigens, cd45 MeSH D08.811.277.352.650.625.700.200 – cdc25 phosphatase MeSH D08.811.277.352.650.625.725 – pyruvate dehydrogenase (lipoamide)-phosphatase MeSH D08.811.277.352.650.700 – 6-phytase MeSH D08.811.277.352.650.850 – pten phosphohydrolase MeSH D08.811.277.352.660 – phosphoric triester hydrolases MeSH D08.811.277.352.660.500 – aryldialkylphosphatase MeSH D08.811.277.352.700 – ribonucleases MeSH D08.811.277.352.700.350 – endoribonucleases MeSH D08.811.277.352.700.350.025 – aspergillus nuclease s1 MeSH D08.811.277.352.700.350.262 – eosinophil cationic protein MeSH D08.811.277.352.700.350.381 – eosinophil-derived neurotoxin MeSH D08.811.277.352.700.350.500 – micrococcal nuclease MeSH D08.811.277.352.700.350.700 – ribonuclease h, calf thymus MeSH D08.811.277.352.700.350.707 – ribonuclease iii MeSH D08.811.277.352.700.350.711 – ribonuclease p MeSH D08.811.277.352.700.350.715 – ribonuclease, pancreatic MeSH D08.811.277.352.700.350.725 – ribonuclease t1 MeSH D08.811.277.352.700.350.810 – RNA-induced silencing complex MeSH D08.811.277.352.700.375 – exoribonucleases MeSH D08.811.277.352.827 – sulfatases MeSH D08.811.277.352.827.070 – arylsulfatases MeSH D08.811.277.352.827.070.060 – n-acetylgalactosamine-4-sulfatase MeSH D08.811.277.352.827.070.250 – cerebroside-sulfatase MeSH D08.811.277.352.827.070.625 – steryl-sulfatase MeSH D08.811.277.352.827.180 – chondroitinases and chondroitin lyases MeSH D08.811.277.352.827.180.175 – chondroitinsulfatases MeSH D08.811.277.352.827.180.175.060 – n-acetylgalactosamine-4-sulfatase MeSH D08.811.277.352.827.180.175.275 – chondro-4-sulfatase MeSH D08.811.277.352.827.500 – iduronate sulfatase MeSH D08.811.277.352.897 – thiolester hydrolases MeSH D08.811.277.352.897.075 – acetyl-CoA hydrolase MeSH D08.811.277.352.897.700 – palmitoyl-coa hydrolase MeSH D08.811.277.352.897.850 – ubiquitin thiolesterase
Sources: en.wikipedia.org
== Structure == These proteins are characterized by having three disulfide bonds in a characteristic motif. Some family members have an additional disulfide bond also in a conserved location. All of these proteins have a helical segment (corresponding to B chain in insulin) followed by a variable-length chain, followed by a domain (A chain in insulin) with two helices pinned against each other via a disulfide bond. These two regions are linked by two or three disulfide bonds. Amongst the different proteins in the family, very little of the sequence is conserved except for the disulfide bonds. The variable-length chains may exhibit large inter-species variation even when the remainder of the sequence is highly conserved; and as is in the case of insulin, sometimes the variable length chain is cleaved out by secretory endoproteases, leaving a two-chain protein held together by disulfide bonds.
Cossacks were expected to provide their own uniforms. While these were sometimes manufactured in bulk by factories owned by the individual host, families often handed down garments or made them within the household. Accordingly, individual items might vary from those laid down by regulation, or be of obsolete pattern. Each host had distinctive uniform colourings. Similar uniforms are in service today amongst the Cossacks of Russia. For most hosts, the basic uniform consisted of the standard loose-fitting tunics and wide trousers typical of Russian regular troops from 1881 to 1908, and shown in the two photographs opposite. In marked contrast the two Caucasian hosts (Kuban and Terek) wore the very long, open-fronted, cherkesska coats with ornamental cartridge loops and coloured beshmets (waistcoats). These have come to epitomize the popular image of the Cossacks. Most hosts wore fleece hats with coloured cloth tops in full dress, and round caps with or without peaks for ordinary duties. These caps were worn sharply slanted to one side by the rank-and-file of Cossack regiments, over hair trimmed longer than that of ordinary Russian soldiers. The two Caucasian hosts wore high fleece caps on most occasions, together with black felt cloaks (burke) in bad weather. Until 1909, Cossack regiments in summer wore white gymnasterkas (blouses) and cap covers of standard Russian army pattern. The shoulder straps and cap bands were in the host colour, as detailed below. From 1910 to 1918, they wore a khaki-grey jacket for field wear.
Selenium (from Greek σελήνη, selene, meaning 'Moon') was discovered in 1817 by Jöns Jacob Berzelius and Johan Gottlieb Gahn. Both chemists owned a chemistry plant near Gripsholm, Sweden, producing sulfuric acid by the lead chamber process. Pyrite samples from the Falun Mine produced a red solid precipitate in the lead chambers, which was presumed to be an arsenic compound, so the use of pyrite to make acid was discontinued. Berzelius and Gahn, who wanted to use the pyrite, observed that the red precipitate gave off an odor like horseradish when burned. This smell was not typical of arsenic, but a similar odor was known from tellurium compounds. Hence, Berzelius's first letter to Alexander Marcet stated that this was a tellurium compound. However, the lack of tellurium compounds in the Falun Mine minerals eventually led Berzelius to reanalyze the red precipitate, and in 1818 he wrote a second letter to Marcet describing a newly found element similar to sulfur and tellurium. Because of its similarity to tellurium, named for the Earth, Berzelius named the new element after the Moon. In 1873, Willoughby Smith found that the electrical conductivity of grey selenium was affected by light. This led to its use as a cell for sensing light. The first commercial products using selenium were developed by Werner Siemens in the mid-1870s. The selenium cell was used in the photophone developed by Alexander Graham Bell in 1879. Selenium transmits an electric current proportional to the amount of light falling on its surface.
=== Neurodegenerative disorders === Huntington disease. No reliable conclusion could be drawn regarding the effectiveness of THC or oral cannabis extract in treating the symptoms of Huntington disease as the available trials were too small to reliably detect any difference Parkinson's disease. Based on a single study, oral CBD extract was rated probably ineffective in treating levodopa-induced dyskinesia in Parkinson's disease. Alzheimer's disease. A 2009 Cochrane Review found insufficient evidence to conclude whether cannabis products have any utility in the treatment of Alzheimer's disease.
== Disadvantages == Limited to protein immunogens (not useful for non-protein based antigens such as bacterial polysaccharides) Potential for atypical processing of bacterial and parasite proteins Potential when using nasal spray administration of plasmid DNA nanoparticles to transfect non-target cells, such as brain cells Cross-contamination when manufacturing different types of live vaccines in same facility
Sources: en.wikipedia.org
The two share the same 29-amino-acid backbone. CJC-1295 carries an additional albumin-binding moiety that markedly extends its residence time in circulation, while the form without that moiety clears faster. Literature sometimes applies the name loosely to either variant.
It has not been approved by major regulatory agencies for any therapeutic indication. Material sold under this name is typically distributed for laboratory research only. Clinical use is not supported by large controlled trials.
Early human studies of the albumin-binding form reported circulation half-lives on the order of several days. The value depends on assay method and study design. Estimates for the form without the binding moiety are considerably shorter.
No. It is a synthetic analogue modeled on the first 29 residues of human GHRH. The substitutions and any linker are laboratory modifications rather than features of the endogenous peptide.